



MONTANA HEALTHCARE PROGRAMS

January 16, 2019

Physician Administered Drug Prior Authorization Criteria for Xolair®

Version 1 published 01-16-19

Xolair® (omalizumab) is an anti-IgE antibody

Indications: Xolair® is used for:

- Moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids
- Chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment

Criteria for Approval:

For Allergic Asthma:

- Must be prescribed by an appropriate specialist or have an annual consult on file. (allergist, pulmonologist or immunologist).
- Member is 6 years of age or older
- Member must have moderate to severe asthma and allergies
- Member must be appropriately using ICS inhaler
- Length of authorization-1 year

For Chronic Idiopathic Urticaria:

- Must be prescribed by an appropriate specialist or have an annual consult on file. (allergist, immunologist, or dermatologist)
- Member is 12 years of age or older
- Must have diagnosis of chronic idiopathic urticaria.
- Must have had an inadequate response to 2 different antihistamine trials of at least 4 weeks each.
- Initial authorization will be for 3 months. Renewals will be granted in 6 month increments if symptoms are sufficiently controlled.

Limitations:

Allergic Asthma: max of 375mg SQ every 2 weeks (refer to dosage chart in package insert)

CIU: max of 300mg SQ every 4 weeks.

Renewal Criteria:

- Member must have been adherent to treatment regimen since last renewal.
- Member has had a positive response to therapy as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations.
- Members already receiving Xolair prior to initiation of prior authorization criteria implementation will be grandfathered. However, renewal criteria must still be met.

References:

1. Xolair® [package insert]. South San Francisco, CA: Genentech, Inc.; 09/2018, Accessed January 10, 2019.